Asset
DEFACTINIB
Revenue
No revenue reported in loaded filings.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02372227 | phase1 | terminated | 2015-01-01 | 2015-10-01 | Verastem, Inc. | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma |
| NCT02913716 | phase1 | completed | 2015-08-01 | 2015-09-01 | Verastem, Inc. | A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects |
| NCT00787033 | phase1 | completed | 2008-12-01 | 2011-03-01 | Verastem, Inc. | A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies |
| NCT06072781 | phase3 | recruiting | 2024-03-18 | 2028-10-15 | Verastem, Inc. | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer |
| NCT04620330 | phase2 | completed | 2020-12-31 | 2023-08-29 | Verastem, Inc. | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer |
FDA applications (0)
This company has no applications containing this asset.